AI-generated summary
This pilot randomized trial in patients with symptomatic irreversible pulpitis compared single 660 nm and 808 nm photobiomodulation with sham irradiation, measuring S100A8/A9 in pulp blood and gingival crevicular fluid. The authors report numerically greater fold increases with laser than with sham, particularly for 660 nm in older participants, but none of the differences reached statistical significance. The study was small, and the authors note that multi-dose protocols are needed.
- Who or what was studied
- Patients with symptomatic irreversible pulpitis (group sizes 14, 13 and 8)
- Wavelengths
- 660, 808 nm
- Limits stated in the abstract
- Small pilot sample with no statistically significant differences between groups, and only a single PBM treatment was tested.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Photobiomodulation (PBM) modulates inflammation and promotes tissue repair. S100A8/A9 is a neutrophil-derived calcium-binding heterodimer that acts as a pro‑inflammatory damage‑associated molecular pattern, serving as a biomarker of inflammation. This study aimed to evaluate the effects of PBM at 660 nm and 808 nm wavelengths on S100A8/A9 levels in pulp blood (PB) and gingival crevicular fluid (GCF) in patients with symptomatic irreversible pulpitis (SIP). Patients diagnosed with SIP were block-randomised into three groups: Group 1 received 660 nm PBM (n = 14), Group 2 received 808 nm PBM (n = 13), and Group 3 received sham irradiation (n = 8). PB and GCF samples were collected pre- and post-irradiation. Laser activation lasted 60 s, delivering energy densities of 17.26 J/cm² (660 nm) and 33.16 J/cm² (808 nm). S100A8/A9 levels were quantified via enzyme-linked immunosorbent assay (ELISA) and analysed using fold change from baseline, Spearman non-linear correlation analysis for age effects, Fisher's exact test, and Kruskal-Wallis tests (α = 0.05). There was inter‑individual variation in baseline S100A8/A9 levels in both PB and GCF. Baseline S100A8/A9 levels were higher in GCF than in PB at the individual level, with no age effect in PB, whereas GCF levels were lower in the 60-80‑year group than in the 45-59‑year group. PBM at 660 nm and 808 nm produced numerically greater fold increases in S100A8/A9 in PB and GCF than sham, particularly for 660 nm in older participants, but these effects did not reach the threshold for statistical significance. This study is the first clinical trial to explore the effect of S100A8/A9 expression in PB and GCF following a single PBM treatment at wavelengths of 660 nm and 808 nm. This pilot study demonstrated that S100A8/A9 can be detected in pulp blood and GCF from patients with SIP and may serve as a potential biomarker for PBM response, although no statistically significant differences were found. Given the cumulative and time-dependent nature of PBM effects, future research should investigate multi-dose protocols to better define its role in managing pulpal inflammation.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 660 nm, 808 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Randomized controlled trial, Inflammation, Biomarker, Fluence, Sham, Statistical significance, Pilot study. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.